Logo

RUBICON RESEARCH LIMITED Share Price

NSE: RUBICON
|
Pharmaceuticals
₹ 1,307.00
-₹67.20 (-4.89%)
1D
Last updated 03 Jul, 2026, 15:48 IST

RUBICON RESEARCH LIMITED Share Price Today

As of 5 Jul 2026, RUBICON RESEARCH LIMITED share price is ₹1,307.00. The stock opened at ₹1,366.60, compared to its previous close of ₹1,374.20. During today's trading session, RUBICON RESEARCH LIMITED share price moved in the range of ₹1,286.30 to ₹1,385.10, with an average price of ₹1,335.70 for the day. Looking at its last 52-week, the stock has touched a low of ₹570.75 and a high of ₹1,468.70. On the performance front, RUBICON RESEARCH LIMITED share price has increased by 97.61% over the last six months and is up 108.05% on a year-on-year basis.

₹1,286.30
4.89% down today
₹1,385.10
1D LOW
1D HIGH

RUBICON RESEARCH LIMITED Returns Calculator

Open
₹1,366.60
High
₹1,385.10
Low
₹1,286.30
Prev. close
₹1,374.20
Circuit
L
H
₹1,045.60
₹1,568.40
52-week
L
H
₹570.75
₹1,468.70

RUBICON RESEARCH LIMITED Shareholder Returns

RUBICON RESEARCH LIMITED Share Price History

Mkt Cap Cr
22,732.70
P/E
92.13
P/B
17.64
ROE
19.14%
D/E
0.20
ROCE
22.56%
Div. Yield
0.11%
EPS(TTM)
11.83
Turnover
0.86
EV/EBITDA
55.38
Net Margin
0.00%
Op. Margin
0.00%
ROA
10.60%
Quick Ratio
0.00
Curr. Ratio
4.23
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Rubicon Research outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Rubicon Research appears overvalued compared to its peers
Step 5 of 5
Earnings
Excellent
Rubicon Research revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,49,048.0039.025.3713.74%0.6117.33%93.240.85%0.5610.90
Divis Laboratories1,77,179.0069.0010.5715.32%0.0019.56%629.490.45%0.5898.19
Torrent Pharmaceuticals1,57,804.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,17,642.0025.472.8711.79%0.0015.66%2.891.06%0.4943.52
Dr. Reddy's Laboratories1,12,368.0027.032.9711.07%0.1812.54%375.780.59%0.6338.68
Zydus Lifesciences1,10,651.0021.604.0818.59%0.3117.35%235.250.09%0.3935.38
Lupin1,09,676.0020.484.8923.76%0.0424.88%659.050.75%0.61129.18
Mankind Pharma1,02,729.0053.006.3011.74%0.3413.13%397.020.04%0.5449.37
Aurobindo Pharma90,608.0025.872.399.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs82,398.9060.2610.1018.21%0.4516.70%10.190.20%0.9713.72

RUBICON RESEARCH LIMITED Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹1,284.27₹853.89₹393.52₹313.57
Other Income₹11.95₹18.50₹25.48₹16.85
Total Revenue₹1,296.22₹872.39₹419.00₹330.42
Total Expenses₹1,101.70₹769.53₹430.05₹396.53
Profit Before Tax₹194.52₹102.86-₹11.05-₹66.11
Tax₹60.16₹11.85₹5.84₹1.01
Profit After Tax₹134.36₹91.01-₹16.89-₹67.12
EPS - Basic₹8.82₹5.98-₹1.11-₹4.41
EPS - Diluted₹8.68₹5.91-₹1.11-₹4.41

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹194.52₹102.86-₹11.05-₹66.11
Income before WC changes₹287.93₹174.17₹35.18-₹38.59
Change in Assets-₹244.21-₹241.49-₹162.98-₹36.16
Change in Liabilities₹154.21₹106.40₹54.87₹20.59
Change in WC-₹90.00-₹135.08-₹108.11-₹15.58
Cash flow from Operations₹159.18₹21.01-₹74.75-₹62.63
Cash flow from Investing-₹64.81-₹68.51-₹33.82-₹54.92
Cash flow from Financing-₹39.81₹43.55₹122.81₹63.05
Total Cash Flow₹54.56-₹3.95₹14.24-₹54.50
Cash (Start of the year)₹50.61₹54.43₹38.67₹84.16
Cash (End of the year)₹104.98₹50.61₹54.43₹38.67

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹388.07₹346.32₹248.12₹231.12
Current Assets₹1,063.37₹763.17₹501.59₹328.40
Total Assets₹1,451.43₹1,109.49₹749.70₹559.52
Current Liabilities₹786.03₹572.50₹361.32₹183.51
Net Current Asset₹277.34₹190.67₹140.27₹144.89
Non-Current Liabilities₹124.42₹151.99₹102.01₹70.61
Equity Capital₹540.99₹385.00₹286.38₹305.40
Total Equity & Liabilities₹1,451.43₹1,109.49₹749.70₹559.52

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹1,073.84₹630.51₹393.52₹400.04
Other Income₹19.68₹26.43₹25.48₹17.38
Total Revenue₹1,093.52₹656.94₹419.00₹417.41
Total Expenses₹870.24₹622.87₹430.05₹400.49
Profit Before Tax₹223.28₹34.07-₹11.05₹16.92
Tax₹55.74₹9.73₹5.84₹0.24
Profit After Tax₹167.54₹24.35-₹16.89₹16.68
EPS - Basic₹11.00₹1.60-₹1.11₹32.91
EPS - Diluted₹10.82₹1.58-₹1.11₹32.91

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹223.28₹34.07-₹11.05₹16.92
Income before WC changes₹291.63₹85.60₹35.18₹44.02
Change in Assets-₹331.90-₹15.99-₹162.98-₹126.42
Change in Liabilities₹96.78₹29.47₹54.87₹20.88
Change in WC-₹235.12₹13.49-₹108.11-₹105.54
Cash flow from Operations₹29.65₹83.20-₹74.75-₹71.10
Cash flow from Investing-₹10.03-₹130.49-₹33.82-₹52.21
Cash flow from Financing-₹34.05₹45.86₹122.81₹65.22
Total Cash Flow-₹14.43-₹1.42₹14.24-₹49.08
Cash (Start of the year)₹40.47₹41.76₹38.67₹78.65
Cash (End of the year)₹25.85₹40.47₹54.43₹29.57

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹390.61₹446.09₹248.12₹280.31
Current Assets₹950.32₹570.51₹501.59₹398.03
Total Assets₹1,340.94₹1,016.60₹749.70₹678.34
Current Liabilities₹588.54₹431.25₹361.32₹180.67
Net Current Asset₹361.78₹139.26₹140.27₹217.36
Non-Current Liabilities₹84.61₹109.48₹102.01₹69.05
Equity Capital₹667.79₹475.87₹286.38₹428.61
Total Equity & Liabilities₹1,340.94₹1,016.60₹749.70₹678.34
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
1307
2301
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 2301
Buy orders: 0%
Sell orders: 100%
Bearish
2
Neutral
4
Bullish
2
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
54.13
Neutral
ATR (14)
72.69
Neutral
STOCH(9,6)
11.35
Bullish
STOCH RSI (14)
0
Bullish
ADX(9)
35.3
Bearish
UO(9)
44.83
Neutral
ROC(12)
-3.3
Bearish
WillR(14)
-79.11
Neutral
Period
Simple value
Exponential vaue
5D
1374.38
1358.37
10D
1380.74
1359.26
20D
1325.12
1313.18
50D
1131.68
1166.54
100D
962.12
1041.74

About RUBICON RESEARCH LIMITED

RUBICON RESEARCH LIMITED logo
ISIN
INE506V01022
Sector Market Cap
₹ 22,732.7 Cr

Rubicon Research Ltd is an India-based pharmaceutical formulations company, which is focused on research and development, with a portfolio of specialty products and drug-device combination products targeting regulated markets, and particularly the United States. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.

RUBICON RESEARCH LIMITED Financial Highlights

  • Revenue: RUBICON RESEARCH LIMITED reported revenue of ₹1,761.69 crore in FY26 vs ₹1,287.90 crore in FY25. It showed an increase of 36.79% on a yearly basis.
  • Operating Profit: RUBICON RESEARCH LIMITED reported an operating profit of ₹320.53 crore in FY26 vs ₹194.52 crore in FY25. It showed an increase of 64.78% on a year-on-year basis.
  • Net Profit: RUBICON RESEARCH LIMITED reported a net profit of ₹246.74 crore in FY26 vs ₹134.36 crore in FY25. It showed an increase of 83.64% on a yearly basis.

RUBICON RESEARCH LIMITED Quarterly Result Highlights

  • RUBICON RESEARCH LIMITED reported revenue of ₹516.53 crore in Mar 2026, compared with ₹479.32 crore in Dec 2025, representing an increase of 7.76% on a quarter-on-quarter (QoQ) basis.
  • RUBICON RESEARCH LIMITED reported an operating profit of ₹98.69 crore in Mar 2026, compared with ₹90.59 crore in Dec 2025, representing an increase of 8.94% on a quarter-on-quarter (QoQ) basis.
  • RUBICON RESEARCH LIMITED reported a profit of ₹76.79 crore in Mar 2026, compared with ₹72.80 crore in Dec 2025, reflecting an increase of 5.48% on a QoQ basis.
  • The earnings per share (EPS) of RUBICON RESEARCH LIMITED stood at ₹8.82 during Mar 2026.
Know more
Promoters
59.86%
FII
7.54%
Other DII
2.88%
Retail and other
22.58%
Mutual funds
7.14%
Foreign institutions - FII
Compare against other stocks
RUBICON RESEARCH LIMITED logo
RUBICON RESEARCH LIMITED
Pharmaceuticals
Add Stock
Add Another

FAQs on RUBICON RESEARCH LIMITED Share Price